To determine the factors associated with peripheral vascular damage in systemic lupus erythematosus patients and its impact on survival from Lupus in Minorities, Nature versus Nurture, a longitudinal US multi-ethnic cohort. Peripheral vascular damage was defined by the Systemic Lupus International Collaborating Clinics Damage Index (SDI). Factors associated with peripheral vascular damage were examined by univariable and multi-variable logistic regression models and its impact on survival by a Cox multi-variable regression. Thirtyfour (5.3%) of 637 patients (90% women, mean [SD] age 36.5 [12.6] [16-87] years) developed peripheral vascular damage. Age and the SDI (without peripheral vascular damage) were statistically significant (odds ratio [OR] ¼ 1.05, 95% confidence interval [CI] 1.01-1.08; P ¼ 0.0107 and OR ¼ 1.30, 95% CI 0.09-1.56; P ¼ 0.0043, respectively) in multi-variable analyses. Azathioprine, warfarin and statins were also statistically significant, and glucocorticoid use was borderline statistically significant (OR ¼ 1.03, 95% CI 0.10-1.06; P ¼ 0.0975). In the survival analysis, peripheral vascular damage was independently associated with a diminished survival (hazard ratio ¼ 2.36; 95% CI 1.07-5.19; P ¼ 0.0334). In short, age was independently associated with peripheral vascular damage, but so was the presence of damage in other organs (ocular, neuropsychiatric, renal, cardiovascular, pulmonary, musculoskeletal and integument) and some medications (probably reflecting more severe disease). Peripheral vascular damage also negatively affected survival. Lupus (2009) 18, 1303-1308.
Introduction
The association between inflammatory rheumatic disease and atherosclerosis is well known. With the improvement of life expectancy in patients with systemic lupus erythematosus (SLE), atherosclerotic vascular events, such as myocardial infarction, stroke, peripheral vascular disease and sudden death, have been recognised as negatively impacting on their outcome. 1, 2 However, to date the relationship between the factors associated with the occurrence of irreversible peripheral vascular damage and its impact on survival has not been studied in these patients.
The presence of anti-phospholipid (aPL) antibodies, vasculitis and vasospasm may also contribute to the occurrence of peripheral vascular damage in SLE patients. 3, 4 In addition, traditional atherosclerosis risk factors and comorbidities, such as hypertension, insulin resistance (metabolic syndrome) and dyslipidaemia, may occur more frequently in lupus patients than in the general population.
We have now studied the factors associated with the occurrence of peripheral vascular damage as determined by the Systemic Lupus International Collaborating Clinics Damage Index or SDI 5 and its impact on survival on SLE patients from Lupus in Minorities, Nature versus Nurture (LUMINA), a US multi-ethnic lupus cohort. We hypothesised that disease activity, damage in other organ systems and, particularly, traditional risk factors will be associated with the occurrence of peripheral vascular damage and that peripheral vascular damage in turn will contribute to these patients' decreased survival.
Patients and methods
Patients LUMINA is a longitudinal study of outcome in lupus. 6 All patients meet the American College of Rheumatology (ACR) criteria for the classification of SLE, 7 have disease duration of 5 years, are 16 years of age, of defined ethnicity (African-American, Hispanic [from Texas and Puerto Rico] or Caucasian), live in the geographic recruitment area of the participating centers (the University of Alabama at Birmingham, the University of Texas Heath Science Center at Houston and the University of Puerto Rico Medical Sciences Campus). The institutional review board of these centers approved the study; written informed consent was obtained from each subject according to the Declaration of Helsinki.
Every patient had a baseline or enrolment visit (T0); follow-up visits were conducted every 6 months during the first year (T0.5 and T1, respectively) and yearly thereafter. At each visit, the patients were interviewed, and physical examination and laboratory tests were performed. Data for missed study visits were obtained by review of all available medical records.
Disease duration was defined as the time elapsing from the date the patients met four ACR diagnostic (TD) criteria for SLE to T0. Duration of follow-up was defined as the period between T0 and the last visit (TL).
Variables
As previously reported, 8 the LUMINA database include variables from the following domains: socioeconomic-demographic, clinical, immunologic, genetic, behavioural and psychological. These variables are measured at T0 and at every subsequent visit. Only the variables included in these analyses will be described.
Variables from the socioeconomic-demographic domain included age, ethnicity, education, poverty (as defined by the US Federal government adjusted for the number of subjects in the household) 9 and smoking. Clinical variables included disease duration, follow-up time, total disease duration, body mass index, disease activity and damage, disease manifestations (myocardial infarction, angina, heart failure, hypertension, cerebrovascular disease, diabetes and nephritis), laboratory variables and medications.
Disease activity was assessed with the Systemic Lupus Activity Measure-Revised (SLAM-R) 10 at T0 and at every visit; the average SLAM-R score for all visits (from TD to TL) was calculated as a measure of disease activity over time. Damage at T0 was measured with the SDI. 5 Peripheral vascular damage was removed from the SDI in these analyses. Peripheral vascular damage was defined per the corresponding domain of SDI as follows: claudication, minor tissue loss (pulp space), significant tissue loss ever (e.g. loss of digit or limb), venous thrombosis with residual swelling, ulceration or venous stasis, all present 6 months. 5 The following laboratory variables were recorded at T0: low-density lipoprotein, serum C-reactive protein (CRP) measured by a highsensitivity immunometric assay (Immulite 2000 Diagnostic Products, Los Angeles, California, USA), and IgG and IgM aPL antibodies (abnormal >13 units/ml IgG phospholipid) measured by enzyme-linked immunoabsorbent assay and/or lupus anti-coagulant (LAC) measured by Staclot test (Diagnostica Stago 92600, Asnieres-Sur-Seine, France). Cumulative exposure to glucocorticoids, hydroxychloroquine, cyclophosphamide, azathioprine, statins, low-dose aspirin, warfarin, low-molecular weight heparin and anti-platelet medications was also recorded.
Statistical analyses
Features from the different domains were compared between those patients who developed peripheral vascular damage and those who did not using Student's t-tests and Chi-square tests for continuous and categorical variables, respectively. Variables with P 0.10 in these analyses were entered into multi-variable logistic regression models to examine their independent association with peripheral vascular damage. Two models were examined; in model 1, the medications were included, whereas in model 2, they were omitted. Age, gender and ethnicity were entered in both models. The association between peripheral vascular damage and mortality was examined by a Cox multi-variable regression, adjusting for variables previously found to be associated with mortality (age, gender, ethnicity, poverty and the damage index [without peripheral vascular damage]). 11, 12 The level of statistical significance was set at 
Results
At the time of these analyses, the cohort consisted of 637 patients; 90% of them were women with a mean (SD) age of 36. 
Univariable analyses
The distribution of damage in the different SDI domains is depicted in Table 1 ; ocular (P ¼ 0.0076), neuropsychiatric (P ¼ 0.0071), renal (P ¼ 0.0230), pulmonary (P ¼ 0.0004), cardiovascular (P ¼ 0.0009), musculoskeletal (P < 0.0001) and integument (P ¼ 0.0033) occurred more frequently in those patients with peripheral vascular damage.
Most of the variables known to be associated with atherosclerosis, such as smoking, dyslipidaemia, obesity and diabetes, were similarly distributed among those patients who had developed peripheral vascular damage and those who had not. However, hypertension, heart failure and nephritis were more frequent in the peripheral vascular damage group, but statistical significance was not reached for hypertension (P ¼ 0.0758, P ¼ 0.023 and P ¼ 0.0081, respectively). Regarding medications, the use of warfarin was much higher in the peripheral vascular damage group than in the group without damage (35.3% vs 7.5%; x 2 ¼ 36.03, P < 0.0001); however, the use of warfarin did not substantially differ among these patients who developed a venous thrombotic peripheral vascular damage event versus those who did not (46.2% vs 53.9%; 
Multi-variable analyses
The multi-variable logistic regression models are depicted in Table 2 In multi-variable analyses, and after adjusting for pertinent variables, peripheral vascular damage was found to be a significant predictor of a diminished survival (hazard ratio ¼ 2.36; 95% CI 1.07-5.19; P ¼ 0.0334).
Discussion
The relationship between SLE and vascular events including cardiovascular, cerebrovascular and peripheral vascular has been well recognised, 13 but no studies to date have focused on the factors associated with the development of peripheral vascular damage in these patients. We are now reporting that peripheral vascular damage occurs in older individuals and in the presence of damage in other organ systems. Furthermore, it seems that peripheral vascular damage has a negative impact on these patients' survival.
At the time these analyses were performed, we noted that 15 of our patients had already developed peripheral vascular damage at T0; such damage had occurred between TD and the T0 or a period of approximately 1.6 years from TD. This observation suggests that in some patients peripheral vascular damage occurs quite early in the disease course and that periodic surveillance of subclinical vascular disease in these patients is warranted; such early damage in the peripheral vascular system has not been observed by other investigators. 14 The prevalence of peripheral vascular damage in our cohort was 5.3% over nearly 6 years of disease duration and included both presumed atherosclerotic and thrombotic events; however, this distinction is not always clear and patients may have experienced both types of events. Although the contributing factors may be different depending on the type of event, more than one factor may be present concomitantly. These considerations, plus the relatively small number of individual peripheral vascular events in our patients, have had precluded us from performing further analyses. The contribution of the peripheral vascular damage domain to the total SDI score is variable; for instance, in a Mexican study involving 210 SLE patients, with a disease duration of nearly 12 years, peripheral vascular damage was reported in 10% of them, 15 whereas in an Argentinean study (n ¼ 197), it occurred in 8.4 % of them at 10 years 16 ; given the observation time in our study, our findings are consistent with those reported in the literature.
Differences between studies may also relate to the number of patients studied and their ethnic and geographic origins. Additionally, when peripheral vascular disease, rather than damage, had been examined, higher prevalence figures had been observed since subclinic vascular disease defined by Doppler abnormalities in the carotid and subclavia territories, which will not be scored in the damage index, are included. 17 As expected, we have observed significant damage in other organ systems in patients with peripheral vascular damage, which has been the case for domains frequently associated with the development of accelerated atherosclerotic and vasculitis, but not with those primarily related to medication side effects (premature gonadal failure, diabetes and malignancy).
The association between age and peripheral vascular damage was predictable, given that endothelial injury from diverse sources tends to accumulate over time. Furthermore, age is an independent contributor to overall damage. 18 In terms of other variables studied, we were surprised about the lack of association between peripheral vascular damage and some variables that have been previously shown to be associated with the occurrence of vascular events, such as smoking, dyslipidaemia, elevated CRP levels and aPL antibodies. 13, 19 Furthermore, even though hypertension, lupus nephritis and, particularly, heart failure were significant in the univariable analyses, they were not retained in the multi-variable models, perhaps because these other factors may impact damage overall which in turn was significantly associated with peripheral vascular damage. Furthermore, damage in general, suggests the presence of an ongoing inflammatory process which characterises this disease. In terms of the aPL antibodies, their lack of association with the occurrence of peripheral vascular damage probably reflects the fact that they were examined at entry into the cohort rather than closer to the time when the damage event occurred.
The association of peripheral vascular damage and medications should not be interpreted as causal but rather as reflecting a more severe disease (azathioprine) or as being used because of the presence of peripheral vascular damage (warfarin) or confounding by indication. The lower frequency of peripheral vascular damage among statin users may relate to their protective effect on the endothelium as postulated by Bruce. 20 Finally, although glucocorticoids have been associated with permanent damage, specially in some specific domains of the SDI (such as musculoskeletal, cardiovascular and ocular), we could not confirm the association with peripheral vascular damage perhaps suggesting their uneven effect on different vascular territories. 14 Peripheral vascular damage had a strong negative impact on survival which is not surprising given the SLE bimodal pattern of mortality as described by Urowitz et al., over 30 years, being the second peak related to atherosclerosis. 2 Even though our study includes a significant number of SLE patients with peripheral vascular damage (n ¼ 34), this number is still small; furthermore, given that about half of our cases had occurred before patients actually entered the cohort, we could not perform time-oriented analyses. In addition, the LUMINA protocol does not include data elements, such as homocysteine levels, immune complexes and folic acid use, which could be important contributors or modulators of the outcome of interest. 3 In summary, even though peripheral vascular damage is infrequent, our analyses indicated that it occurs in older SLE patients and it is associated with the presence of damage in other organ systems. In addition, peripheral vascular damage is associated with a diminished survival confirming the bimodal pattern of mortality in SLE patients.
